OR WAIT null SECS
Transparency Life Sciences (TLS), a clinical-stage drug development company based on open innovation, announced that the first patient has been enrolled in an innovative ulcerative colitis clinical trial designed to assess the feasibility of replacing most conventional patient site visits with data collected using a combination of decentralized methods, including digital measurements, telemonitoring, remote video visits with clinical trial staff and blood collections by visiting nurses. In addition, the study is the first to allow key clinical endpoint assessments to be made by the subjects’ own gastroenterologists, rather than via designated sub-investigators affiliated with the trial.
The study was commissioned and is funded by a global biopharmaceutical company, and it is being conducted in collaboration with Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, and a founding hospital of Partners Healthcare.
Read the full release.